The third objective was to evaluate the impact of a previous SARS-CoV-2 infection on vaccine-induced mucosal IgG and IgA profiles and neutralizing responses following one, two and three doses of mRNA vaccine, or after a breakthrough infection. This evidence concerns the gene CD79A and infection.